Kala Pharmaceuticals, Inc. (KALA)

US — Healthcare Sector
Peers: MNK  LFCR  LSDI  ALIM  ADMP  SHPH  DERM  AKAN  ORGO  BFRI  GHSI  CPHI  ALKS  NBIX  ITCI  DCPH  DVAX 

Automate Your Wheel Strategy on KALA

With Tiblio's Option Bot, you can configure your own wheel strategy including KALA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol KALA
  • Rev/Share 0.0
  • Book/Share 4.5199
  • PB 4.636
  • Debt/Equity 3.0182
  • CurrentRatio 1.9899
  • ROIC -0.9641

 

  • MktCap 26906508.0
  • FreeCF/Share -4.3206
  • PFCF -0.9813
  • PE -0.7423
  • Debt/Assets 0.357
  • DivYield 0
  • ROE -3.6929

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

KALA BIO Announces Chief Executive Officer Transition
KALA
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017.

Read More
image for news KALA BIO Announces Chief Executive Officer Transition

About Kala Pharmaceuticals, Inc. (KALA)

  • IPO Date 2017-07-20
  • Website https://www.kalarx.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Todd Bazemore
  • Employees 38
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.